E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10011401 |
E.1.2 | Term | Crohn's disease |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the trial is to compare disease activity following a single s.c. dose of NNC142-0002 to placebo in subjects with moderately to severely active CD, measured 4 weeks after administration. |
|
E.2.2 | Secondary objectives of the trial |
• To compare safety and tolerability of NNC142-0002 and placebo
• To compare change in disease activity at other time-points than Week 4, clinical response and remission, between subjects treated with NNC142-0002 and subjects receiving placebo
• To compare the quality of life (QoL) between subjects treated with NNC142-0002 and subjects receiving placebo
• To compare use of concomitant medication for CD between subjects treated with NNC142-0002 and subjects receiving placebo
• To describe the pharmacokinetics (PK) of NNC142-0002 during treatment
• To compare the pharmacodynamics (PD) response, by assessment of various biomarkers, between subjects treated with NNC142-0002 and subjects receiving placebo
• To describe the immunogenicity of NNC142-0002 |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Endoscopy Biopsy Sub-Study (no separate protocol title, date and version)
Optional Exploratory Objectives at Specific Sites:
To describe PK and explore PD in endoscopically obtained biopsy specimens taken from gut mucosa of the subset of subjects consenting for the sub-study |
|
E.3 | Principal inclusion criteria |
- Men and women (not pregnant and not nursing) of ≥18 and ≤75 years of age
- Subjects with CD for at least 3 months having active disease with a CDAI score of ≥220 and ≤450 and evidence of inflammation confirmed by a C-reactive protein (CRP) level ≥10 mg/L (or ≥1.0 mg/dL) or endoscopic verification
- Biologic-naïve subjects or biologic-experienced for the treatment of CD having discontinued due to lack of efficacy to only one biologic therapy (primary or secondary failure), intolerance to therapy, or other reasons (e.g. drug holiday). |
|
E.4 | Principal exclusion criteria |
• Any of the following: symptomatic bowel obstruction, short bowel syndrome, ileostomy or colostomy, surgical bowel resection within 6 months prior to randomisation or clinically relevant un-drained abscess
• History of dysplasia or malignancy in the colon
• Any ongoing chronic or active infectious disease or microbial infection requiring systemic oral or intravenous treatment against infection within 1 month prior to randomisation
• Body mass index (BMI) ≥38.0 kg/m^2 |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is change in disease activity assessed by the Crohn’s disease activity index (CDAI) from baseline to Week 4. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
a) Number and frequency of adverse events (AEs) from baseline to Weeks 12 and 24
b) Immunogenecity of NNC142-0002 at week 24 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
a) Week 12 and 24
b) Week 24 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Endoscopy Biopsy Sub-Study |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 24 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
European Union |
Canada |
Israel |
Russian Federation |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 0 |